ID   RMUG-L
AC   CVCL_3157
SY   RMUGL
DR   BioSample; SAMN03151923
DR   BioSample; SAMN03472785
DR   CGH-DB; 346-2
DR   CGH-DB; 9364-4
DR   Cosmic; 2429303
DR   GEO; GSM1001421
DR   GEO; GSM1001422
DR   JCRB; IFO50319
DR   Wikidata; Q54950734
RX   CelloPub=CLPUB00481;
RX   PubMed=2083224;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=17671176;
RX   PubMed=19154404;
RX   PubMed=22246397;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a SNG-II derivative. Originally thought to originate from a 62 year old female patient with an ovarian mucinous cystadenocarcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00421.
CC   Population: Japanese.
CC   Doubling time: 53 hours (PubMed=2083224).
CC   Discontinued: JCRB; IFO50319; true.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 8,9,11
ST   D16S539: 12,13,14
ST   D5S818: 6,12,13
ST   D7S820: 8,9,12
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 15,16,17
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3170 ! SNG-II
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 21
//
RX   CelloPub=CLPUB00481;
RA   Kuno H., Yoshida T.;
RT   "Detection of human papillomavirus types 16, 18, and 33 in cell lines
RT   derived from human genital organs by polymerase chain reaction.";
RL   Res. Commun. Inst. Ferment. Osaka 18:6-12(1997).
//
RX   PubMed=2083224;
RA   Sakayori M., Nozawa S., Udagawa Y., Chin K., Lee S.-G., Sakuma T.,
RA   Iizuka R., Wada Y., Yoshida S., Takeda Y.;
RT   "Biological properties of two newly established cell lines (RMUG-S,
RT   RMUG-L) from a human ovarian mucinous cystadenocarcinoma.";
RL   Hum. Cell 3:52-56(1990).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567;
RA   Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Promoter hypermethylation contributes to frequent inactivation of a
RT   putative conditional tumor suppressor gene connective tissue growth
RT   factor in ovarian cancer.";
RL   Cancer Res. 67:7095-7105(2007).
//
RX   PubMed=19154404; DOI=10.1111/j.1349-7006.2008.01065.x;
RA   Sato S., Itamochi H., Kigawa J., Oishi T., Shimada M., Sato S.,
RA   Naniwa J., Uegaki K., Nonaka M., Terakawa N.;
RT   "Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an
RT   effective regimen for mucinous adenocarcinoma of the ovary: a
RT   potential treatment strategy.";
RL   Cancer Sci. 100:546-551(2009).
//
RX   PubMed=22246397; DOI=10.3892/or.2012.1626;
RA   Sato N., Saga Y., Mizukami H., Wang D., Fujiwara H., Takei Y.,
RA   Machida S., Ozawa K., Suzuki M.;
RT   "Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor
RT   cells lacking KRAS gene mutations.";
RL   Oncol. Rep. 27:1336-1340(2012).
//